在线观看人与动牲交视频_夜夜高潮次次欢爽AV女_奇米在线视频观看_欧美精品七区_色悠久久综合网_少妇潮喷无码白浆水视频

美國(guó)Entelos

Entelos is the leader in predictive biosimulation.

Entelos partners with global pharmaceutical and biotechnology organizations worldwide to develop effective new treatments for disease and dramatically reduce the time and cost needed to develop them.

Using its patented PhysioLab technology, Entelos develops dynamic large-scale computer models of human disease. Each PhysioLab platform provides a framework for integrating data (e.g., genomic, proteomic, physiologic, environmental) in the context of a disease or therapeutic area, focusing on understanding and determining clinical responses to potential treatment. Virtual patients are created within this framework to represent real patient subpopulations. Entelos builds and customizes its PhysioLab systems using thousands of peer-reviewed papers, the expertise of its in-house research teams and world-class scientific advisors, and the proprietary information of its collaboration partners.

Using a PhysioLab platform, scientists create virtual patients and simulate experiments and clinical trials in silico (in computer) that could take months or years to do in the laboratory or clinic, increasing the productivity of the drug discovery and development process. Using in silico R&D, Entelos has helped its pharmaceutical partners to:

Advance compounds and eliminate non-promising programs
Advance complex clinical strategies to meet efficacy, regulatory, and marketing requirements
Evaluate in-licensing opportunities
Save time and reduce patient requirements for clinical trials
Identify competitive advantages
Decide which therapeutic indication to pursue for a compound
Prioritize targets and compounds in a therapeutic area portfolio

Entelos provides integrated expertise in the areas of metabolism and cardiovascular function, immunology and inflammation, and respiratory function. Entelos currently has PhysioLab platforms available for use by multiple customers in the areas of asthma, obesity, type 1 and type 2 diabetes, rheumatoid arthritis, and cholesterol metabolism. The Company is developing models for use in cardiovascular and skin sensitization (skin allergy) applications, and plans to develop PhysioLab systems in such other areas as metabolic syndrome, chronic obstructive pulmonary disease (COPD), osteoporosis, and Alzheimer's disease.

Access to Entelos expertise and technology is available through R&D partnerships, research agreements, licenses, and strategic alliances.